Pharmaceutical

Eli Lilly pays $10m upfront for Organovo’s FXR agonist

Organovo’s lead asset FXR314 will be investigated in a Phase II trial for inflammatory bowel disease (IBD).

Feb 27, 2025 - 06:00
Eli Lilly pays $10m upfront for Organovo’s FXR agonist
Organovo’s lead asset FXR314 will be investigated in a Phase II trial for inflammatory bowel disease (IBD).
Read the original article

Tags:

Previous Article

RedHill and Hyloris sign agreement for Bekinda’s development

Next Article

FDA grants breakthrough status to Grin Therapeutics’ radiprodil

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How pharmacy deserts are putting the health of Black and Latino Americans at risk

How pharmacy deserts are putting the health of Black an...

Nov 11, 2023

Man receives the first eye transplant plus a new face. It’s a step toward one day restoring sight

Man receives the first eye transplant plus a new face. ...

Nov 9, 2023

EMA validates BMS’s repotrectinib application to treat cancer

EMA validates BMS’s repotrectinib application to treat ...

Jan 3, 2024